共 22 条
[1]
(1999)
[2]
pp. 274-286, (1994)
[3]
Wynn Owen P.A., Castle D.J., Late-onset Schizophrenia: Epidemiology, diagnosis, management and outcomes, Drugs and Aging, 15, 2, pp. 81-89, (1999)
[4]
Hammerlein A., Derendorf H., Lowenthal D.T., Pharmacokinetic and pharmacodynamic changes in the elderly: Clinical implications, Clin Pharmacokinet, 35, 1, pp. 49-64, (1998)
[5]
Markowitz J.S., Brown C.S., Moore T.R., Atypical antipsychotics: Part I. Pharmacology, pharmacokinetics, and efficacy, Ann Pharmacother, 33, pp. 73-85, (1999)
[6]
Sweet R.A., Pollack B.G., New atypical antipsychotics: Experience and utility in the elderly, Drugs Aging, 12, 2, pp. 115-127, (1998)
[7]
Brown C.S., Markowitz J.S., Moore T.R., Et al., Atypical antipsychotics: Part II. Adverse effects, drug interactions, and costs, Ann Pharmacother, 33, pp. 210-217, (1999)
[8]
Tandon R., Milner K., Jibson M.D., Antipsychotics from theory to practice: Integrating clinical and basic data, J Clin Psychiatry, 60, SUPPL., pp. 21-28, (1999)
[9]
Maixner S.M., Mellow A.M., Tandon R., The efficacy, safety, and tolerability of antipsychotics in the elderly, J Clin Psychiatry, 60, SUPPL., pp. 29-41, (1999)
[10]
Adverse effects of the atypical antipsychotics, J Clin Psychiatry, 59, SUPPL., pp. 17-22, (1998)